1. Pink Sheet
  2. >>Compliance
  3. >>Distribution/Supply Chain

COVID-19 & Ukraine War Underpin EU Moves To Secure Medicines Supply

 
• By Ian Schofield

Concerns by the drug industry over “complex and burdensome” regulatory requirements regarding security of supply could be addressed in the upcoming revision of the EU pharmaceutical legislation, suggests a report on the European Commission’s “structured dialog” process for tackling medicine supply chain vulnerabilities.

Filling vials
The commission has proposed actions to address weaknesses in the medicines supply chain • Source: Shutterstock

A new “risk matrix” methodology for identifying “critical medicines” in the EU. A study on optimizing public procurement of medicines to be published in the fourth quarter of 2022. And a mechanism for national authorities in Europe to further exchange information on supplies of raw materials, intermediates or active substances from different manufacturing sites.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Distribution/Supply Chain

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

 
• By Jessica Merrill

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.

US Pharma Tariff Reprieve May Be Ending

 
• By Jessica Merrill

Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

More from Compliance

US FDA Finds ‘Significant’ Data Integrity Breaches In CRO Raptim Studies

 
• By Urtė Fultinavičiūtė

The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.

US Pharma Tariff Reprieve May Be Ending

 
• By Jessica Merrill

Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.

UK Promises To ‘Turbocharge’ Clinical Trials As US Tariff Threat Remains

 
• By Andrew McConaghie

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.